Terapia basata sull'uso di derivati antibiotici per il trattamento di melanoma, cancro al colon-retto, prostata, seno e polmoni.
Cancer Treatment Technologies
Curing cancer is certainly one of the big challenges of the 21st century. Our knowledge of cancer has greatly improved in the last two decades, however with over 100 different known cancers, this is not going to be an easy challenge to overcome. With this collection, we would like to highlight some of the technologies developed within our network to prevent and fight, and also help rehabilitate patients.
Combination of macetaxine mepesuccinate and venetoclax against nucleophosmin mutated acute myeloid leukemia.
Blocking of the "heme synthesis-export" system, to interfere with energy remodelling and the state of cancer cells.
Therapeutic tool with a chimeric complex characterized by a strong antimetastatic activity and significant selectivity.
Peptides with anticancer activity capable of targeting the hexokinase 2 (HK2) enzyme in different types of tumors.
Palladium compounds with vinyl or butadienyl fragments, having a strong antiproliferative activity on various tumor cell types.
Delivery of mir-126 for the targeted treatment of the tumor, with a low pharmacological dose and with reduced secondary side effects.
Immunofluorescence-labeled cell nuclei for automatic identification of diseased cells in any type of human body tissue.
Vesicular systems formed by double-structure asymmetric bilayers for the delivery of genetic material
Asymmetric vesicles to carry genetic material for anticancer therapies, vaccines and for the treatment of genetic diseases.
Therapeutic combination of ET and a CDK4 / 6 inhibitor with a reduced calorie period, for the treatment of breast cancer.
Compound 1-piperidine propionic acid as an adjuvant in the treatment of several types of solid tumors that overexpress SerpinB3.
Combination of an HIF-1 inhibitor and a TLR-3 agonist, for use as an antitumor agent of solid prostate cancer.
Oleandrin from the Nerium Oleander plant as a drug to counter the growth of glioma and to slow down tumor progression.
Method capable of classifying TNBC patients at high risk of recurrence and / or metastasis without the need for an invasive biopsy.
Method for the in vitro diagnosis of the degree of risk of recurrence or persistence of head and neck cancer and related kit.
Synthetic production of water-soluble salts of sulfoxides, both in the form of a racemic mixture and in the enantiopure form.
New Notch signalling inhibitors with chalconic-based chemical structure, for use against both solid and haematological tumors.
Therapeutically active compounds based on multi-target inhibitors, for the prevention and treatment of cancer and inflammation.
Molecular therapeutic approach to reverse resistance to chemotherapy based on conventional cytostatics, such as cisplatin.
Isothiocyanate and isoselencyanate compounds with theranostic and chemopreventive properties, for use as fluorescent probes.
New bio-tolerable anticancer antibodies able to block the internalization of iron not bound to transferrin in cancer cells.
New isoindolin derivatives activating AMPK for the prevention and treatment of metabolic disorders, such as type II diabetes and obesity.
Peptides for the treatment of diseases associated with impaired cell motility, migration and adhesion such as angiogenesis, invasion and tumor metastases.
Marker genes and a computational method capable of predicting the survival of a patient 5 years after the removal of tumor tissue.
RNA aptamers capable of inhibiting DNA methyltransferase 1, an enzyme responsible for DNA methylation, closely related to the development of tumors.
Pharmaceutical compositions comprising of bacteriophage-lipid conjugates, for immuno-therapeutic strategies against cancer and infectious agents.
Nucleotide aptamers capable of binding to exosomes isolated from breast cancer cells, for liquid biopsies and tumor growth inhibition.
Protein that acts as a biological drug capable of interfering with multiple characteristics of the tumor microenvironment, for the treatment of cancer.
Peptides and peptidomimetics for the inhibition of protein-protein interactions of the SHP2 phosphatase, for treatmenting various neoplasms and RASopathies.
Thioridazine analogue compounds for the treatment of acute myeloid leukemia with reduction of adverse effects on the central nervous system.
Method and kit to identify the genetic signature of breast cancer, identifies in detail the genetic variations of each individual tumor.
Solution which can be used both as a tracer for the surgical removal guided by radiation and for diagnostic imaging and radiometabolic therapy.
First inhibitory compounds of the MAGL enzyme with reversible action, to treat pathologies like sclerosis, Alzheimer, tumors with lower side effects.
Monoclonal antibodies which enables to address the cure where it is required enhancing the immune response, thereby promoting tumor regression.
Combinations of substituents that are able to meet one or more of the medical needs and have significant and selective anticancer activity.
Isolation of extracellular vesicles from plasma of cancer patients and the use of isolated vesicles for the administration of drugs.
Innovative chemotherapeutics charaterized by high cytotoxic effects on cancer cells and poor toxicity on healthy tissues cells.
Method for the real time measure of Irinotecan drug's concentration in patient's plasma and then to establish the optimal dose for the therapy.
Method to measure the concentration of the drug Imatinib in patient's plasma and then to establish the optimal dose for his therapy.
Method which aims to replace damaged neurons by restoring brain function lost or compromised by neurodegenerative diseases or trauma.
Device able to recognize and analyze exosomes from biological fluids allowing to bind the target and recognize it with a high degree of specificity.
Complexes for the treatment of solid drug-resistant metastatic tumors that aims to reduce the corrateral effects and avoid accumulation in retention organs.
Method that allows to perform a semi-quantitative analysis of MR data to evaluate the response to neo-adjuvant radio-chemotherapy treatments.
Compounds with multiple action wich reduces the risk of interaction between different drugs and greater simplicity of administration to the patient.
The present invention refers to a new synthesis method and new molecules that have an increased antitumor action.
Compounds for diagnistic-therapeutic appoach to inflammatory processes related to diseases like atherosclerotic lesions and several tumors.
Biomarkers found in easily accessible biofluids are a non invasive and promising approach to improve bladder cancer diagnostic accuracy.
Small molecule that enables the control of immunity over the long period and effectively reduces disease symptoms in a dose-dependent way.
Anticancer agent that can be used in cancer therapy thanks to its interaction with the cancer cells that allows to block their energy metabolism.
Microdispersed system for application in localization and treatment that would let schedule surgery on several days, reducing cost of hospitalization.
Nanoconstruct and ultrasound activation set-up able to treat tumor cell and induce them to death with no need of chemotherapeutic drugs.
Device that measures electrical characteristics of areas of living tissue to improve the accuracy of methods for cancer diagnosis.
Method that, through an extracorporeal circulation procedure, allows to eliminate unwanted biological and/or chemical entities from biological fluids.
Method for melanoma early-stage diagnosis by automatically recognizing and identifying nevi through thermography and photogrammetry.
Synthesis of a leptin antagonist tetrapeptide, in which the central amino acids consist of aspartic acid and phenylalanine.
Control of the anomalous metabolic cancer process and its reversal obtained by changing the ion and energy transfer through the cell membrane.
Peptides binding to human thymidylate synthase for the treatment of cancer. The peptides bind to each subunit of the protein dimer interface.
The syntesis of derivaties of the pyrrolocyclohepta oxazoles showed potent antitumor activity on the NCI panel with GI50 reaching the nanomolar level.
The invention refers to in vivo stable branched peptides, conjugated to functional units for diagnosis or therapy of tumours.